Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.56 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.56 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.56 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.56 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
| ▸ | GABRE | P78334 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.35 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL336468 | 0.97 | GABRA1 (0.54) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL1872649 | 0.84 | — | — | |
| SCHEMBL5035847 | 0.84 | — | — | |
| SCHEMBL116683 | 0.84 | — | — | |
| Hydrochloric Acid SCHEMBL31320031 | 0.82 | GABRA5 (0.44) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Hydrochloric Acid SCHEMBL6178563 | 0.82 | GABRA5 (0.44) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| Trifluoroacetic Acid SCHEMBL4194562 | 0.82 | GABRA1 (0.45) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL19544694 | 0.79 | GABRA1 (0.52) | GABRA1TSHRGABRG2GABRB3GABRA5 | |
| SCHEMBL1965395 | 0.78 | — | — | |
| SCHEMBL21039274 | 0.77 | LMNA (0.41) | GABRA1TSHRGABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 736 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | claimed |
| EP-4161921-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| CN-115916776-A | Collagen 1 translation inhibitors and methods of use thereof | 艾尼莫生物科技公司 | 2023-04-04 | — | — | CN | claimed |
| WO-2021252555-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2021-12-16 | — | — | WO | claimed |
| CN-110023315-B | Novel compound or pharmacologically acceptable salt thereof | 国立研究开发法人理化学研究所 | 2021-11-12 | — | — | CN | claimed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | claimed |
| EP-3796900-B1 | TRITERPENE AMINE DERIVATIVES | DFH THERAPEUTICS (US) | 2026-04-08 | — | — | EP | disclosed |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | PMV PHARMACEUTICALS, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4155300-B1 | SUBSTITUTED QUINOLINE ANALOGS AS ALDEHYDE DEHYDROGENASE 1A1 (ALDH1A1) INHIBITORS | US HEALTH (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2025-12-23 | — | — | US | disclosed |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | KUDA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | INCYTE CORP (US) | 2025-10-16 | — | — | US | disclosed |
| CN-1172932-C | Benzo (5,6) cyclohepta (1,2-b) pyridine derivs useful for inhibition of farnesyl-protein transferase | ���鹫˾ | 2004-10-27 | — | — | CN | disclosed |
| EP-0993460-B1 | BENZO(5,6)CYCLOHEPTA(1,2B)PYRIDINE DERIVATIVES USEFUL FOR INHIBITION OF FARNESYL PROTEIN TRANSFERASE | SCHERING CORP (US) | 2004-09-15 | — | — | EP | disclosed |
| CN-1348442-A | Novel sulfonamide compounds and uses thereof | MERCK & CO INC (US) | 2002-05-08 | — | — | CN | disclosed |
| EP-1159263-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | Merck & Co., Inc. (US) | 2001-12-05 | — | — | EP | disclosed |
| CN-1267298-A | Benzo (5,6) cyclohepta (1,2-b) pyridine derivs useful for inhibition of farnesyl-protein transferase | SCHERING CORP (US) | 2000-09-20 | — | — | CN | disclosed |
| WO-2000050391-A1 | NOVEL SULFONAMIDE COMPOUNDS AND USES THEREOF | MERCK & CO., INC. (US) | 2000-08-31 | — | — | WO | disclosed |
| US-6051582-A | ANTITUMOR, ANTICANCER AGENTS | SCHERING CORPORATION (US) | 2000-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12503473-B2 | Triazolopyrimidine compounds and their use in treating cancer | ABCC4, ABCB1, SLC16A3 | GABRA1 2512/4885TSHR 1609/4885GABRG2 2019/4885 |
| US-20250320212-A1 | TRICYCLIC UREA COMPOUNDS AS JAK2 V617F INHIBITORS | JAK2, JAK1, JAK3 | GABRA1 3145/4885TSHR 1623/4885GABRG2 2739/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | GABRA1 4024/4885TSHR 4068/4885GABRG2 4293/4885 |
| US-20250346588-A1 | IMIDAZOPYRIDINE AND OXAZOLOPYRIDINE DERIVATIVES AND ANALOGS THEREOF, METHODS OF PREPARATION THEREOF, METHODS OF HIF-1/2A PATHWAY INHIBITION, AND INDUCTION OF FERROPTOSIS | HIF1AN, HIF1A, EGLN2 | GABRA1 3202/4885TSHR 1368/4885GABRG2 3672/4885 |
| US-20260027097-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, BRCA1 | GABRA1 4643/4885TSHR 2806/4885GABRG2 4605/4885 |
| US-12570645-B2 | Uses of p53 x-ray co-crystal structures | TP53, TP53BP1, ERCC2 | GABRA1 4443/4885TSHR 1092/4885GABRG2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.